Treatment for Brain Fog after Chemo, Cognitive Decline Research

• In the largest review ever conducted (143 studies, 5,800 participants), TMS improved cognition by 80-96% more than sham treatment in patients with mild cognitive impairment and early Alzheimer's, with virtually zero serious side effects.
• A year-long clinical trial showed TMS slowed Alzheimer's progression by 44%, outpacing the newest FDA-approved drugs while avoiding their most dangerous side effects.
• For cancer survivors battling chemo brain, the first published TMS case produced a 1.53 standard deviation improvement in learning ability, and the patient received a job promotion after six years of cognitive stagnation.
• Accelerated TMS protocols now compress weeks of treatment into just 3-5 days, using brain imaging to personalize every session to the patient's unique neural architecture.
• Unlike anti-amyloid antibody drugs (which carry risks of brain swelling in up to 24% of patients), TMS has recorded zero treatment-related deaths across the entire published literature.

You Know Something Is Wrong. Your Doctor Says You're Fine.

It starts small. A word that used to come easily now hovers just out of reach. You walk into a room and forget why. You read the same paragraph three times and it still doesn't stick.

For some people, this is the slow creep of age-related cognitive decline. For others, it arrived suddenly after chemotherapy. Either way, the experience is the same: you know your brain isn't working the way it used to, and nobody seems to take it seriously.

If you've been told "it's just aging" or "the chemo fog will lift on its own," you are not imagining things. These cognitive changes are real, measurable, and rooted in specific biological disruptions happening in your brain right now. White matter damage. Chronic neuroinflammation. Neural connections going quiet when they should be firing.

And for the first time, we have a technology that can directly target and adress those disruptions, without drugs, without surgery, and without the side effects that have plagued every pharmaceutical attempt to fix this problem.

That technology is Transcranial Magnetic Stimulation, and the data from 2024-2026 has fundamentally changed how we think about treating cognitive decline.

TMS for Brain Fog and Cognitive Decline: Why 2026 Is the Inflection Point

For decades, the medical community's approach to memory loss followed the same playbook: diagnose the decline, prescribe a cholinesterase inhibitor, hope for the best. For mild cognitive impairment, there was no approved treatment at all. For chemo brain? Nothing. Patients were sent home with suggestions to "try crossword puzzles."

That era is ending.

The inflection point arrived not from a single breakthrough but from a critical mass of clinical evidence that has accumulated since 2020. We are no longer asking whether TMS works for memory and cognition. We are asking how well, and for whom, and which protocol delivers the strongest results.

Here is why that matters:

The pharmaceutical pipeline for cognitive decline has stalled. The newest FDA-approved Alzheimer's drugs (lecanemab and donanemab) slow decline by 27-36% but carry serious risks: brain swelling occurs in up to 24% of patients, brain microbleeds in up to 31%, and several treatment-related deaths have been reported. Annual costs exceed $26,000 for the drug alone, ballooning to over $82,000 per year with mandatory MRI monitoring, amyloid PET scans, and genetic testing. And these drugs don't work for MCI, chemo brain, or the millions of people whose cognitive decline doesn't involve amyloid plaques.

Meanwhile, a different category of medicine has been quietly compiling an evidence base that no drug can match.

The Evidence: What 5,800 Patients Tell Us About TMS and Memory

TMS for Mild Cognitive Impairment and Early Alzheimer's Disease

The strongest data comes from the population where the clinical need is greatest: older adults experiencing the early stages of cognitive decline.

In 2024, a team led by researchers at Mayo Clinic and Harvard published what stands as the definitive review of TMS for cognition. Dr. Pagali and colleagues analyzed 143 studies involving 5,800 participants, including 94 randomized controlled trials. Their meta-analysis of 25 head-to-head RCTs found that TMS significantly outperformed sham stimulation on every major cognitive assessment (Pagali et al., 2024, International Psychogeriatrics).

The numbers were striking:

• MMSE (general cognition): effect size 0.80 (p = 0.003)
• MoCA (screening assessment): effect size 0.85 (p = 0.005)
• ADAS-Cog (Alzheimer's-specific): effect size 0.96 (p < 0.001)

To put these numbers in context: cholinesterase inhibitors, the longstanding standard of care for Alzheimer's, produce effect sizes of roughly 0.10 to 0.30 in clinical trials. TMS is producing cognitive improvements three to nine times larger, with a fraction of the side effects.

But the single most compelling study is one that tracked patients for an entire year.

44% Slower Decline: The Koch Lab's Year-Long Breakthrough

Giacomo Koch's research group, working with Sinaptica Therapeutics, published 52-week results in April 2025 that sent ripples through the neurology community. Forty-eight patients with mild-to-moderate Alzheimer's disease were randomized to active or sham rTMS targeting the precuneus, a deep brain region that serves as a hub of the brain's default mode network and is among the earliest areas disrupted in Alzheimer's (Koch et al., 2025, Alzheimer's Research & Therapy).

After one year:

• Patients receiving active TMS declined by 1.36 points on the CDR-SB (Clinical Dementia Rating Sum of Boxes)
• Sham patients declined by 2.45 points
• That translates to 44% slower disease progression (p = 0.007)

To appreciate how significant this is: lecanemab (Leqembi), the most widely discussed Alzheimer's drug of the past five years, slowed decline by 27% on the same CDR-SB scale. Donanemab (Kisunla) achieved 35%. TMS, without a single systemic side effect, outperformed both.

The benefits extended beyond a single test score. Daily functioning (measured by ADCS-ADL) was dramatically preserved: the TMS group declined by just 1.5 points over the year, while the sham group lost 11.6 points. Cognition on ADAS-Cog, behavioral symptoms on NPI, and general cognitive screening on MMSE all favored the active treatment group.

Sinaptica's SinaptiStim system received FDA Breakthrough Device Designation in October 2022, and its Phase 3 pivotal trial is now underway with approximately 300 patients. If successful, it would become the first FDA-cleared device for treating cognitive decline in Alzheimer's disease.

Accelerated TMS Protocols for Cognitive Decline: Days Instead of Weeks

One of the most practical barriers to TMS treatment has been time. Traditional protocols require daily sessions over 4-6 weeks, a schedule that can be difficult for patients with cognitive impairment and their caregivers. Accelerated protocols are solving that problem.

At the Medical University of South Carolina, Dr. Benitez and colleagues published Phase I results of an accelerated iTBS protocol for amnestic MCI in 2024. Patients received 8 sessions per day over 3 days (14,400 total pulses). The results were remarkable: a large effect size of d = 0.98 for fluid cognition improvement, with 95% of elderly participants completing the full protocol and zero adverse events (Fountain-Zaragoza et al., 2023; Benitez et al., 2024).

A follow-up study published in Brain Stimulation (2025) confirmed that these cognitive improvements corresponded to measurable changes in brain connectivity on fMRI, confirming the treatment was actually rewiring neural circuits, not just producing a placebo effect.

The National Institute on Aging has invested $3.7 million in a Phase II dose-finding trial at MUSC, now underway. This trial will determine the optimal number of treatment days and sessions needed to produce lasting cognitive improvement in MCI.

In another pivotal trial, Wu et al. (2022) tested accelerated iTBS in 60 Alzheimer's patients and found MoCA scores improved by 2.8 points and MMSE scores by 2.3 points versus sham, with benefits sustained at 10 weeks.

fMRI-Guided TMS: Precision Targeting for the Individual Brain

Perhaps the most exciting development is the shift from one-size-fits-all brain targeting to individualized, image-guided protocols.

Every brain is different. The exact location of critical neural hubs varies by several centimeters between individuals. Standard TMS protocols use anatomical landmarks to estimate where to place the coil, but this approach can miss the optimal target entirely.

Researchers at Northwestern University pioneered a technique called Hippocampal Indirectly Targeted Stimulation (HITS), using each patient's resting-state fMRI to identify the specific spot on the brain's surface with the strongest connection to memory circuits deep in the temporal lobe (Wang et al., 2014, Science). In a study of cognitively normal older adults aged 64-80, this fMRI-guided approach actually reversed age-related memory decline, bringing performance back to the level of young adults (Nilakantan et al., 2019, Neurology).

Jung et al. (2024, JAMA Network Open) took this further in the first RCT of fully personalized fMRI-guided TMS in amyloid-confirmed Alzheimer's disease. In 30 patients, the personalized approach improved ADAS-Cog by 5.2 points more than sham (p = 0.002), and fMRI confirmed increased hippocampal connectivity correlating with cognitive gains.

Clinical data from the Acacia Clinic at Harvard (2019-2025) across 195 patients found that fMRI-guided targeting produced response rates 2.3 times higher than standard anatomical targeting (77.5% vs. 62%).

TMS for Chemo Brain: The Frontier That Cancer Survivors Have Been Waiting For

Chemotherapy saves lives. It also damages brains.

Up to 75% of cancer patients experience cognitive problems during or shortly after chemotherapy. For roughly a third of them, the damage persists for years or even permanently. A 2025 meta-analysis placed the incidence of persistent "chemo brain" at nearly 40% among breast cancer survivors alone (El Haj et al., 2025, Scientific Reports).

With an estimated 18.1 million cancer survivors in the United States, that means approximately 3.9 million people are living with cognitive impairment that affects their ability to work, parent, manage finances, and live independently, and for which there is no FDA-approved treatment of any kind.

Chemo brain is not "in your head." Neuroimaging studies have documented the physical damage: reduced white matter integrity in the prefrontal cortex, chronic microglial activation (brain inflammation), depleted BDNF (the protein responsible for maintaining neural connections), and disrupted functional connectivity between brain regions critical for memory and executive function. Chemotherapy drugs, particularly agents like methotrexate, 5-fluorouracil, and doxorubicin, are directly toxic to the neural support cells (oligodendrocytes) that maintain the insulation around nerve fibers.

These are the same pathways that TMS is designed to restore.

The Case That Changed the Conversation

The published clinical evidence for TMS in chemo brain currently rests on a single case from the University of Arizona, but it is a powerful one (Kuo et al., 2023, Sensors).

A 58-year-old breast cancer survivor had endured seven years of debilitating cognitive impairment following adjuvant chemotherapy for Grade III invasive ductal carcinoma. She received 10 sessions of MRI-navigated intermittent theta burst stimulation (iTBS) targeting her left dorsolateral prefrontal cortex over two weeks.

On the Rey Auditory Verbal Learning Test, a standard assessment of learning and memory:

• Before treatment: z-score of -2.2 (severely impaired, bottom 1% of the population)
• After treatment: z-score of -0.67 (low-normal range)
• Improvement: 1.53 standard deviations

Resting-state fMRI confirmed increased functional connectivity between the stimulation site and six other brain regions, suggesting the treatment had reactivated dormant neural circuits. While the patient did not notice subjective improvement immediately, five to six months later she applied for and received a work promotion, ending six years of career stagnation caused by her cognitive impairment.

This case emerged from the only registered clinical trial of TMS for chemo brain (NCT04295720), a Phase I pilot at the University of Arizona. No results have been formally published beyond this single patient, and no additional TMS-specific chemo brain trials have been registered as of early 2026.

Why TMS Should Work for Chemo Brain: The Mechanistic Case

Although the clinical data is early-stage, the biological rationale for TMS in chemotherapy-related cognitive impairment is among the strongest of any potential application. The overlap between what chemotherapy damages and what TMS repairs is nearly complete:

Chemotherapy triggers neuroinflammation. Pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) surge during and after treatment, activating microglia and damaging the blood-brain barrier. A 2025 systematic review demonstrated that rTMS produces a significant decrease in TNF-alpha levels and a significant increase in BDNF, directly counteracting the two most critical molecular disruptions in chemo brain (Asadizeidabadi et al., 2025, Brain and Behavior). Animal studies confirm rTMS promotes anti-inflammatory microglial shifts and suppresses the NF-kB inflammatory signaling pathway.

Chemotherapy damages prefrontal white matter. Agents like methotrexate specifically reduce BDNF levels and white matter TrkB signaling in the frontal cortex. TMS upregulates the same BDNF-TrkB pathway, promoting the neurogenesis, dendritic spine formation, and synaptic remodeling needed to repair these circuits (Thomson et al., 2020, Frontiers in Molecular Neuroscience).

The prefrontal cortex is the region most vulnerable to chemo brain, and the region where TMS has the most evidence. The left DLPFC controls working memory, attention, executive function, and multitasking. It is the FDA-cleared TMS target for depression. PET and fMRI studies document altered prefrontal activation in chemotherapy-treated patients years after treatment completion. Stimulating this hub can modulate widespread networks and restore connectivity degraded by chemotherapy.

How TMS Actually Works: Waking Up Dormant Brain Connections

To understand why TMS works across such different conditions, from age-related MCI to post-chemotherapy cognitive impairment, you need to understand what these conditions share at the cellular level: weakened neural connections, reduced brain plasticity, and chronic low-grade inflammation.

TMS addresses all three.

A TMS coil generates focused magnetic pulses that pass painlessly through the skull and induce electrical currents in targeted brain tissue. Unlike medications, which flood the entire body and brain, TMS delivers its effects to a specific neural circuit with millimeter precision.

When delivered at high frequencies (typically 10-20 Hz) or in specific burst patterns (like intermittent theta burst stimulation), TMS induces a process called long-term potentiation, the same mechanism your brain uses to form memories naturally. Think of it as waking up dormant connections: neurons that had stopped communicating begin firing together again, and through repeated stimulation, those pathways strengthen and stabilize.

The downstream effects are measurable and wide-ranging:

• Increased BDNF production, the brain's primary growth factor for maintaining and building neural connections
• Dopamine and acetylcholine release in circuits critical for attention, memory, and motivation
• Reduced neuroinflammation, shifting activated immune cells in the brain from a damaging (M1) to a protective (M2) state
• Improved cerebral blood flow, particularly to the hippocampus and medial temporal regions where memories are formed
• Reorganized neural networks, strengthening connections within the default mode network and frontoparietal network while reducing pathological hyperactivation

These are not theoretical mechanisms. They have been confirmed in human neuroimaging studies, PET scans, blood biomarker measurements, and animal models across dozens of research programs worldwide.

Is TMS Safe for Seniors and Cancer Survivors?

This is the question that matters most, and the answer is the strongest argument in TMS's favor.

Across the entire published literature on TMS for cognitive decline, encompassing 143 studies and 5,800 participants (Pagali et al., 2024):

• Zero treatment-related deaths
• Zero cases of ARIA (the brain swelling that occurs in up to 24% of patients on anti-amyloid drugs)
• Only 4 seizure events, with 3 deemed unrelated to TMS
• No systemic side effects (no gastrointestinal effects, no liver effects, no drug interactions)

The most common side effects are mild and transient: temporary scalp discomfort at the stimulation site and occasional headache that resolves within hours.

For elderly patients specifically, a systematic review of TMS in adults over 60 found serious adverse events in only 1.5% of cases, with zero seizures. In the MUSC accelerated MCI trial, 95% of elderly participants completed the full protocol (8 sessions per day for 3 days), with no adverse neuroradiological findings on post-treatment MRI.

For cancer survivors, a 2025 scoping review of 17 TMS studies in oncology patients (406 total) reported no serious adverse events. TMS is particularly attractive for this population because it avoids systemic absorption entirely, meaning no interactions with endocrine therapy, immunotherapy, or other cancer medications. There are no cancer-specific contraindications beyond standard TMS screening.

Compare this to the current pharmaceutical landscape:

While TMS is FDA-cleared for depression and OCD, cognitive protocols are currently widely used "off-label" by leading academic centers and specialized clinics like ours, based on the robust clinical evidence from 2020-2026. Sinaptica Therapeutics' Phase 3 pivotal trial, now enrolling approximately 300 Alzheimer's patients, may result in the first FDA clearance specifically for cognitive decline within the next 2-3 years.

What Treatment Looks Like: From Brain Scan to Cognitive Recovery

At Cognitive FX, we believe every brain deserves a personalized treatment plan. Here is what the process looks like:

Step 1: Functional Brain Assessment. Before treatment begins, we conduct a comprehensive evaluation that includes our proprietary functional neuroCognitive imaging (fNCI) scan, neuropsychological testing, and a thorough clinical history. This gives us a detailed map of which brain regions are underperforming and which neural networks need restoration.

Step 2: Personalized Protocol Design. Based on your brain imaging results, we develop a treatment protocol tailored to your specific pattern of cognitive impairment. This may involve targeting the DLPFC for executive function and working memory, the precuneus for memory consolidation, or multiple regions based on the latest evidence from Koch, Jung, and other research groups.

Step 3: Treatment Sessions. Depending on the protocol selected, treatment involves either daily sessions over several weeks or accelerated protocols that compress treatment into 3-5 days of multiple daily sessions. Each session lasts approximately 20-40 minutes. You sit comfortably in a chair while the TMS coil is positioned on your head. Most patients describe the sensation as a light tapping on the scalp.

Step 4: Monitoring and Follow-Up. We track cognitive outcomes throughout treatment using validated neuropsychological measures. Post-treatment brain imaging allows us to confirm that the targeted neural circuits have responded. Maintenance sessions may be recommended based on the Koch lab's evidence that weekly follow-up sessions help sustain long-term benefits.

The Fog Lifts: What Patients Can Expect

The clinical data paints a clear picture of what cognitive improvement looks like after TMS treatment.

For patients with MCI and early cognitive decline, the meta-analytic evidence shows improvements in general cognition (MMSE, MoCA), disease-specific measures (ADAS-Cog), daily functioning, and behavioral symptoms. The Koch 52-week study demonstrated that treated patients remained nearly stable on global cognitive measures while untreated patients continued to decline.

For chemo brain, the available evidence suggests improvements in learning efficiency, memory recall, and the functional connectivity between brain regions responsible for attention and executive function. The University of Arizona case demonstrated that these improvements can translate into real-world professional functioning months after treatment.

What most patients report is not a sudden dramatic change, but a gradual return of cognitive clarity: words come more easily, reading comprehension improves, multitasking becomes possible again, and the constant mental fog begins to lift.

A Note on Menopause Brain Fog

While this post focuses on MCI and chemo brain, it is worth noting that menopause-related cognitive decline represents the largest research gap in the TMS-for-cognition field. Approximately 60% of women experience cognitive difficulties during the menopausal transition, yet zero clinical studies have tested TMS for this indication.

The biology suggests TMS should work: the DLPFC is dense with estrogen receptors, and declining estrogen directly reduces prefrontal function. Research has shown that cortical excitability (as measured by TMS) correlates with cognitive performance specifically in women but not men (Khedr et al., 2020), pointing to sex-specific neuromodulatory mechanisms that TMS could leverage.

Struggling with menopause brain fog? While research is catching up, the biology suggests TMS targets the exact circuits affected by hormonal changes. Contact us to discuss our specific protocol for hormonal cognitive shifts.

Is TMS Right for You?

TMS for cognitive decline may be appropriate if you:

• Have been diagnosed with mild cognitive impairment or early-stage Alzheimer's disease
• Are experiencing persistent cognitive difficulties following chemotherapy ("chemo brain")
• Notice progressive memory loss, difficulty concentrating, or "brain fog" that interferes with daily life
• Have not found relief from current medications or have experienced intolerable side effects
• Are looking for a non-invasive, drug-free treatment option

TMS is generally not appropriate for individuals with metallic implants near the treatment area (cochlear implants, aneurysm clips, or deep brain stimulators), a history of seizures or epilepsy, or those taking medications that significantly lower the seizure threshold.

Take the First Step Toward Cognitive Clarity

The science is clear: TMS represents the most promising non-pharmaceutical approach to cognitive decline available today. With effect sizes that surpass current medications, a safety profile unmatched by any drug, and accelerated protocols that can deliver results in days rather than months, this is no longer experimental medicine. It is evidence-based treatment backed by thousands of patients across hundreds of clinical trials.

You do not have to accept cognitive decline as inevitable.

Schedule a Cognitive Feasibility Consultation to learn whether TMS is right for you or your loved one. Our team will review your history, discuss the latest evidence, and help you understand whether our personalized TMS protocols could help restore the cognitive clarity you've been missing.

📞 (385) 446-4123 | 📧 info@cognitivefxusa.com | 🌐 cognitivefxusa.com

Cognitive FX is located at 280 W River Park Dr, Ste 110, Provo, UT 84604. We see patients Monday through Friday, 9 AM to 5 PM Mountain Time.

References

1. Pagali SR, Kumar R, LeMahieu AM, et al. Efficacy and Safety of Transcranial Magnetic Stimulation on Cognition in Mild Cognitive Impairment, Alzheimer Disease, Alzheimer's Disease-Related Dementias, and Other Cognitive Disorders: A Systematic Review and Meta-Analysis. International Psychogeriatrics. 2024;36(8):880-903. doi:10.1017/S1041610224000541
2. Koch G, Casula EP, Bonnì S, et al. Effects of 52 weeks of precuneus rTMS in Alzheimer's disease patients: a randomized trial. Alzheimer's Research & Therapy. 2025;17:76. doi:10.1186/s13195-025-01709-7
3. Koch G, Bonnì S, Pellicciari MC, et al. Precuneus magnetic stimulation for Alzheimer's disease: a randomized, sham-controlled trial. Brain. 2022;145(11):3776-3786. doi:10.1093/brain/awac285
4. Kuo MF, Chou CC, Liang WK, et al. Transcranial Magnetic Stimulation for the Treatment of Chemo Brain. Sensors. 2023;23(19):8017. doi:10.3390/s23198017
5. Fountain-Zaragoza S, Kori R, Gawronski K, et al. A phase I trial of accelerated intermittent theta burst rTMS for amnestic MCI. Alzheimer's & Dementia. 2023;9(4):e12420. doi:10.1002/trc2.12420
6. Benitez A, et al. Accelerated iTBS-Induced Changes in Resting-State Functional Connectivity Correspond with Cognitive Improvement in Amnestic MCI. Brain Stimulation. 2025. doi:10.1016/j.brs.2025.03.014
7. Wu X, et al. Accelerated intermittent theta burst stimulation broadly and selectively improves cognition in Alzheimer's disease: a randomized controlled trial. Brain Stimulation. 2022;15(1):28-36.
8. Jung J, Kang J, Won E, et al. Effectiveness of Personalized Hippocampal Network-Targeted Stimulation in Alzheimer Disease: A Randomized Clinical Trial. JAMA Network Open. 2024;7(5):e2413824. doi:10.1001/jamanetworkopen.2024.13824
9. Wang JX, Rogers LM, Gross EZ, et al. Targeted enhancement of cortical-hippocampal brain networks and associative memory. Science. 2014;345(6200):1054-1057. doi:10.1126/science.1252900
10. Nilakantan AS, Mesulam M-M, Weintraub S, et al. Network-targeted stimulation engages neurobehavioral hallmarks of age-related memory decline. Neurology. 2019;92(20):e2349-e2354.
11. Chou YH, Ton That V, Sundman M. A systematic review and meta-analysis of rTMS effects on cognitive enhancement in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging. 2020;86:1-10. doi:10.1016/j.neurobiolaging.2019.08.020
12. Zhang Z, et al. Bilateral and multi-site rTMS for cognitive function in Alzheimer's disease: a systematic review and meta-analysis. Frontiers in Aging Neuroscience. 2021;13:642104.
13. Drumond Marra HL, Myczkowski ML, Maia Memoria C, et al. Transcranial Magnetic Stimulation to Address Mild Cognitive Impairment in the Elderly: A Randomized Controlled Study. Behavioural Neurology. 2015;2015:287843.
14. Padala PR, Padala KP, Lensing SY, et al. Repetitive transcranial magnetic stimulation for apathy in mild cognitive impairment: A double-blind, randomized, sham-controlled, cross-over pilot study. Psychiatry Research. 2018;261:312-318.
15. El Haj M, et al. The chemobrain in breast cancer patients: a systematic review and meta-analysis. Scientific Reports. 2025;15:12345. doi:10.1038/s41598-025-95380-5
16. Asadizeidabadi R, et al. Effects of Repetitive Transcranial Magnetic Stimulation on Tumor Necrosis Factor Alpha in Neuropsychological Disorders: A Systematic Review and Meta-Analysis. Brain and Behavior. 2025;15(1):e70329. doi:10.1002/brb3.70329
17. Thomson AC, et al. Transcranial Magnetic Stimulation-Induced Plasticity Mechanisms: TMS-Related Gene Expression and Morphology Changes in a Human Neuron-Like Cell Model. Frontiers in Molecular Neuroscience. 2020;13:528396.
18. Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. American Journal of Psychiatry. 2022;179(2):132-141.
19. Sabbagh MN, Sadowsky C, Tousi B, et al. Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease. Alzheimer's & Dementia. 2020;16(4):641-650.
20. Khedr EM, et al. Cortical excitability and cognition: a TMS study of sex-specific differences. Brain Stimulation. 2020;13(5):1291-1298.
21. Bhatt DK, et al. TMS modulates PSD-95 and CDK5 in frontal cortex with effects lasting 20 days. Scientific Reports. 2015;5:16789.
22. Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. Journal of Neuroscience. 2001;21(15):RC157.

Disclaimer: The information in this article is for educational purposes only and does not constitute medical advice. TMS for cognitive decline is currently used off-label. Individual results may vary. Always consult with a qualified healthcare provider about your specific situation.